claim: leronlimab used in two patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu, removed from icu and extubated with reduced pulmonary inflammation
evidence_1: our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. jacob lalezari, m.d., interim chief medical officer of cytodyn, commented, these preliminary results give hope that leronlimab may help hospitalized patients with covid-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.", "the treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting sars-cov-2 causing the coronavirus disease 2019 (covid-19).", 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  "moreover, a phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in hiv-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.", "clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with hiv with no reported drug-related serious adverse events (saes).")